You searched for Cybin - Page 24 of 61

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions Cybin to provide solutions amid significant demand, with more than 18 million people in the … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD”

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mind Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders Innovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering … Continue reading “Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics”

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments

Pure Extracts commences study into psilocybin-based active treatments Study set to be carried out at Toronto Institute of Pharmaceutical Technology, supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Study will delve into carrying out conformity testing, stability testing for psilocybin products thereby commencing the R&D that will ultimately take place at Pure Extracts’ purpose-built … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments”

QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Upcoming Study on Psilocybin-Based Nasal Gel, Oral Tablets and Capsules

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released the timetable and milestones for a proprietary study. The study is designed to evaluate the formulation, manufacturing and clinical bioavailability of psilocybin-based, rapid-onset active treatments for a nasal gel as well as oral tablets and … Continue reading “QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Upcoming Study on Psilocybin-Based Nasal Gel, Oral Tablets and Capsules”

Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market

Health Canada recently granted psilocybin testing access to selected physicians Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021 In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government … Continue reading “Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Announces API Synthesis of Multiple Tryptamine Derivatives

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing Nov. 15, 2020, as contemplated by the terms of a contribution agreement (the “ transaction agreement”) dated Dec. 4, 2020. According … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Announces API Synthesis of Multiple Tryptamine Derivatives”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for its upcoming sponsored clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development”

Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin

U.S. taking actionable steps toward acceptance of psilocybin States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of … Continue reading “Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin”

Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs Cybin (NEO: CYBN), a mushroom life sciences company, … Continue reading “Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy”

Site Search

Company Search

Search Results for: Cybin